867 related articles for article (PubMed ID: 33723124)
61. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB
Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874
[TBL] [Abstract][Full Text] [Related]
62. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
63. Cannabinoids in the management of difficult to treat pain.
Russo EB
Ther Clin Risk Manag; 2008 Feb; 4(1):245-59. PubMed ID: 18728714
[TBL] [Abstract][Full Text] [Related]
64. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.
Walsh KB; McKinney AE; Holmes AE
Front Pharmacol; 2021; 12():777804. PubMed ID: 34916950
[TBL] [Abstract][Full Text] [Related]
65. Beyond THC and Endocannabinoids.
Pacher P; Kogan NM; Mechoulam R
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():637-659. PubMed ID: 31580774
[TBL] [Abstract][Full Text] [Related]
66. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
[TBL] [Abstract][Full Text] [Related]
67. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists.
Gerra G; Zaimovic A; Gerra ML; Ciccocioppo R; Cippitelli A; Serpelloni G; Somaini L
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):46-52. PubMed ID: 19832688
[TBL] [Abstract][Full Text] [Related]
68. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
69. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
70. Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats.
Parker LA; Mechoulam R
Integr Physiol Behav Sci; 2003; 38(2):133-45. PubMed ID: 14527182
[TBL] [Abstract][Full Text] [Related]
71. The therapeutic potential of cannabis and cannabinoids.
Grotenhermen F; Müller-Vahl K
Dtsch Arztebl Int; 2012 Jul; 109(29-30):495-501. PubMed ID: 23008748
[TBL] [Abstract][Full Text] [Related]
72. [Use of cannabinoids in palliative medicine].
Ernst G; Kongsgaard UE
Tidsskr Nor Laegeforen; 2008 Apr; 128(7):822-5. PubMed ID: 18389029
[TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F
Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
[TBL] [Abstract][Full Text] [Related]
74. Cannabis sativa: Much more beyond Δ
Alves P; Amaral C; Teixeira N; Correia-da-Silva G
Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
[TBL] [Abstract][Full Text] [Related]
75. Cannabinoids for gastrointestinal diseases: potential therapeutic applications.
Di Carlo G; Izzo AA
Expert Opin Investig Drugs; 2003 Jan; 12(1):39-49. PubMed ID: 12517253
[TBL] [Abstract][Full Text] [Related]
76. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
77. Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases.
Thapa D; Warne LN; Falasca M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834122
[TBL] [Abstract][Full Text] [Related]
78. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
79.
Pellati F; Borgonetti V; Brighenti V; Biagi M; Benvenuti S; Corsi L
Biomed Res Int; 2018; 2018():1691428. PubMed ID: 30627539
[TBL] [Abstract][Full Text] [Related]
80. Recent advantages in cannabinoid research.
Mechoulam R
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():16-20. PubMed ID: 10575284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
